A Phase Ia/ Ib Study of HS387 in Subjects With Advanced Solid Tumors
Condition: Advanced Solid Cancers · Sponsor: Zhejiang Hisun Pharmaceutical Co. Ltd.
About this study
This is a Phase Ia/Ib, dose escalation and dose expansion study to evaluate the safety, tolerability, PK, and preliminary efficacy of HS387 in subjects with advanced solid tumors. It includes two parts: the dose escalation study (Phase Ia) and the dose expansion study (Phase Ib)
This description comes directly from the study's public registry record.
Talk to the study team
WEI QU · 8618067913551 · wei.qu@hisunpharm.com
Always discuss trial participation with your own doctor first.
Locations (1)
| Zhejiang Cancer hospital | Hangzhou, Zhejiang, China | Recruiting |
Follow this study
Save your interest here for when the public record changes — results posted, or the study's status changes. Email alerts for this study aren't switched on yet.
We keep this only about this public record, and never email you without alerts being switched on. Want it removed at any time? Email hello@eichor.com. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07092748